Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate

Cellular Immunology

Volumn 266, Issue 1, 2010, Pages 104-110

  Bae, Woo Kyun ^b   Umeyama, Akemi ^c   Chung, Ik Joo ^b   Lee, Je Jung ^a,b   Takei, Masao ^a  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cytokine combination; Dendritic cells; Type I interferon's; Uncarinic acid C

Indexed keywords

ALPHA INTERFERON; CD83 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12P70; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE; T6 ANTIGEN; TRITERPENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCARINIC ACID C; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; COCULTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; UNCARIA; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD40; CANCER VACCINES; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTAXIS; DENDRITIC CELLS; ENZYME INHIBITORS; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; T-LYMPHOCYTES; TH1 CELLS; TOLL-LIKE RECEPTOR 4; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

UNCARIA RHYNCHOPHYLLA;

EID: 77958460504     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.09.004     Document Type: Article

References (27)

1. Lee J.S., Kim J., Kim B.Y., Lee H.S., Ahn S., Chang Y.S. Inhibition of phospholipase Cγ1 and cancer cell proliferation by triterpene esters from Uncaria rhynchophylla. J. Nat. Prod. 2000, 63:753-756.
2. Takei M., Umeyama A., Lee J.-J. The possible use of terpene compounds in DC immunotherapy against cancer. Rec. Pat. End. Met. Immune Drug Dis. 2010, 4:69-74.
3. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 106:245-252.
4. Lanzavecchia A., Sallustoa A.F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
5. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:2555-2558.
6. Wynn T.A. Th-17: a giant step from Th1 and Th2. Nat. Immunol. 2005, 6:1069-1070.
7. Tao C.M., Shea J.J. What does it mean to be just 17?. Nature 2006, 1441:166-168.
8. Steinman R.M. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nature Med. 2007, 13:139-145.
9. O'garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 2001, 8:275-278.
10. Conroy H., Marshall N.A., Mills K.H.G. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008, 27:168-180.
11. Okamoto M., Sato M. Toll-like receptor signaling in anti-cancer immunity. J. Med. Invest. 2003, 50:9-24.
12. Trinchieri G., Scott P. The role of interleukin 12 in the immune response disease and therapy. Immunol. Today 1994, 45:487-494.
13. Trepialas R., Pedersen A.E., Berntsen A., Met O., Hansen M.H., et al. Characterization of monocyte-derived dendritic cells maturated with IFN-alpha. Scand. J. Immunol. 2006, 26:2824-2832.
14. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. Alpa-type-1 polarized dendritic cells; a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004, 64:5934-5937.
15. Lee B.A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type 1 interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
16. Biron C.A. Interferons alpha and beta as immune regulators - a new look. Immunity 2001, 14:661-664.
17. Farrar J.D., Murphy K.M. Type I interferons and T helper development. Immunol. Today 2000, 21:484-489.
18. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of 18,991, a randomised phase III trial. Lancet 2008, 372:117-126.
19. Feldman D.R., Kondagunta G.V., Schwartz L., Patil S., Ishiii N., DeLuca J., et al. Phase II trial of tegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 2008, 6:25-30.
20. Takei M., Umeyama A., Arihara S. T-cadinol and calamenene induce dendritic cells from human monocytes and drive Th1 polarization. Eur. J. Pharmacol. 2006, 537:190-199.
21. Gately M.K., Renzetti L.M., Magram J. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998, 16:495-521.
22. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Mouse Toll-like receptor 4, MD-2 complex mediates lipopolysaccharaide-mimetic signal trans diction by Taxol. J. Biol. Chem. 2000, 275:2251-2254.
23. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'garra A., Murphy K.W. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 26:547-549.
24. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U. The interleukin-12/interleukin-12 receptor systems: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998, 16:495-521.
25. Orth J.D., McNiven M.A. Dynamin at the actin-membrane interface. Curr. Opin. Cell Biol. 2003, 15:31-39.
26. Wheeler A.P., Wells C.M., Smith S.D., Vega F.M., Henderson R.B., Tybulewicz V.I. Rac 1 and Rac 2 regulate macrophage morphology but are not essential for migration. J. Cell Sci. 2006, 119:2749-2757.
27. Kalinski P., Mailliard R.B., Giermasz A. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. 2005, 5:1303-1315.